The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s HP (high potency) APIs market report forecasts the HP (high potency) APIs market size to grow to $36.14 Billion by 2027, with a CAGR (compound annual growth rate) of almost 8%.

Learn More On The HP (High Potency) APIs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/hp-high-potency-api-global-market-report

HP (High Potency) APIs Market Size Forecast

The global HP (high potency) APIs market is expected to grow from $24.53 billion in 2022 to $26.65 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The high potency APIs market is expected to grow from $36.14 billion in 2027 at a CAGR of 7.9%.

North America held the largest HP (high potency) APIs market share, and Middle East was the fastest-growing region in 2022.

Key HP (High Potency) APIs Market Driver ­– Rise In Number Of Cancer Cases Coupled With Increasing Sales Of Cancer Drugs

According to the World Health Organization’s International Agency for Research on Cancer (IARC) report, the cancer burden is expected to increase by 29.5 million new cases and 16.4 million deaths by 2040, globally. Moreover, 70% of deaths from cancer occur in middle and low-income countries. Therefore, the growing incidence of cancer cases is projected to upsurge revenues for the high potency APIs market.

Request for A Sample Of The Global HP (High Potency) APIs Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2814&type=smp

Key HP (High Potency) APIs Market Trend – Focusing On Strategies

The companies dealing in the high potency APIs market are focusing on strategies such as production facility expansion and mergers and acquisitions to maintain their position in the competitive business environment. For instance, in June 2022, MilliporeSigma, a US-based global life science business, opened the doors to its $65 million facility for the production of high-potency active pharmaceutical ingredients (HPAPI), with an emphasis on cancer treatments. In January 2020, Piramal Pharma Solutions (PPS) declared expenditure of $19 million to enhance its operation in Aurora, Ontario, Canada, with an additional 975 m2 of production space in a new wing for API production, including the production of HPAPI for potent compounds down to an OEL of 1 mcg/m3.

HP (High Potency) APIs Market Segment

1) By Type: Innovative HPAPI, Generic HPAPI

2) By Synthesis Type: Synthetic HPAPI, Biotech HPAPI

3) By Therapeutic Application: Oncology, Harmonal Disorder, Glaucoma, Other Therapeutic Applications (Respiratory Disorders, CVD, Diabetes, Cosmetology, and Erectile Dysfunction)

HP (High Potency) APIs Market Major Players and Strategies

Major players in the HP (high potency) APIs market are Eli Lily and Company, Novartis AG, Bristol-Myers Squibb Company, Roche Diagnostics Ltd., Sanofi, Hospira Inc., BASF SE, Covidien PLC., Boehringer Ingelheim GmbH, and Merck & Co. Inc., Sigma Aldrich Corporation, Bayer AG, Carbogen Amcis AG, Lonza, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Mylan Inc., AbbVie, AstraZeneca PLC., and GlaxoSmithKline PLC.

In December 2021, SK Capital Partners, a US-based private investment firm, acquired a majority shareholding in SEQENS for an undisclosed amount. Through this acquisition, SEQENS is better positioned as a more potent and concentrated participant in the international markets for specialised ingredients and pharmaceutical solutions. Wavelength Pharmaceuticals, an existing SK Capital portfolio business that is a global manufacturer and developer of active medicinal ingredients, and SEQENS engaged in a combination concurrent with the acquisition. SEQENS is a France-based developer and manufacturer of custom High-Potency APIs.

The HP (High Potency) APIs Global Market Report 2023 covers regional data on HP (high potency) APIs market size, HP (high potency) APIs market trends and drivers, opportunities, strategies, and HP (high potency) APIs market competitor analysis. The countries covered in the HP (high potency) APIs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

High-potency APIs refer to the substances that, at very low doses, cause a biological response. Traditionally, cytotoxic substances and sex hormones like estrogen are used as examples of HPAPIs. Compared to standard APIs, highly potent active pharmaceutical ingredients (HPAPI) are nonetheless effective at considerably lower dosage levels, but their potency poses unique handling issues.

View More Reports Related To The HP (High Potency) APIs Market –

Pharmaceutical API Manufacturing Global Market Report 2023

Pharmaceutical Drugs Global Market Report 2023

Pharmaceutical Processing Seals Global Market Report 2023

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: